NR4A1 and breast cancer: According to the results of a recent meta-analysis, ovarian function suppression (OFS) + AI was able to lower the absolute risk of recurrence to five to 10 years for patients with premenopausal hormone receptor-positive (HR+) BC compared with OFS + SERM (3), and bone density could be maintained by using bisphosphonates to reduce fractures resulting from AIs (4).